Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 127

1.

Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.

McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network .

J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263.

PMID:
30103338
2.

Structural characteristics of the central nervous system in Friedreich ataxia: an in vivo spinal cord and brain MRI study.

Dogan I, Romanzetti S, Didszun C, Mirzazade S, Timmann D, Saft C, Schöls L, Synofzik M, Giordano IA, Klockgether T, Schulz JB, Reetz K.

J Neurol Neurosurg Psychiatry. 2018 Jun 26. pii: jnnp-2018-318422. doi: 10.1136/jnnp-2018-318422. [Epub ahead of print] No abstract available.

PMID:
29945881
3.

Does arterial hypertension influence the onset of Huntington's disease?

Valcárcel-Ocete L, Fullaondo A, Alkorta-Aranburu G, García-Barcina M, Roos RAC, Hjermind LE, Saft C, Frontali M, Reilmann R, Rickards H; REGISTRY investigators of the European Huntington’s Disease Network (EHDN), Zubiaga AM, Aguirre A.

PLoS One. 2018 May 23;13(5):e0197975. doi: 10.1371/journal.pone.0197975. eCollection 2018.

4.

Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data.

Ferrea S, Groiss SJ, Elben S, Hartmann CJ, Dunnett SB, Rosser A, Saft C, Schnitzler A, Vesper J, Wojtecki L; Surgical Approaches Working Group of the European Huntington’s Disease Network (EHDN).

J Neurol. 2018 Jul;265(7):1573-1579. doi: 10.1007/s00415-018-8880-1. Epub 2018 May 3.

PMID:
29725840
5.

Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study.

Beckmann H, Bohlen S, Saft C, Hoffmann R, Gerss J, Muratori L, Ringelstein EB, Landwehrmeyer GB, Reilmann R.

Gait Posture. 2018 May;62:451-457. doi: 10.1016/j.gaitpost.2018.03.039. Epub 2018 Apr 7.

PMID:
29660633
6.

Cannabinoids for Treatment of Dystonia in Huntington's Disease.

Saft C, von Hein SM, Lücke T, Thiels C, Peball M, Djamshidian A, Heim B, Seppi K.

J Huntingtons Dis. 2018;7(2):167-173. doi: 10.3233/JHD-170283.

PMID:
29562549
7.

Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.

Fatoba O, Kloster E, Reick C, Saft C, Gold R, Epplen JT, Arning L, Ellrichmann G.

Exp Neurol. 2018 Apr;302:112-128. doi: 10.1016/j.expneurol.2018.01.001. Epub 2018 Jan 6.

PMID:
29309751
8.

Laquinimod treatment in the R6/2 mouse model.

Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R.

Sci Rep. 2017 Jul 10;7(1):4947. doi: 10.1038/s41598-017-04990-1.

9.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642124
10.

Identifying modifiers of Huntington's disease progression.

Saft C.

Lancet Neurol. 2017 Sep;16(9):679-680. doi: 10.1016/S1474-4422(17)30179-5. Epub 2017 Jun 20. No abstract available. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642122
11.

Prospective Evaluation of Predictive DNA Testing for Huntington's Disease in a Large German Center.

Ibisler A, Ocklenburg S, Stemmler S, Arning L, Epplen JT, Saft C, Hoffjan S.

J Genet Couns. 2017 Oct;26(5):1029-1040. doi: 10.1007/s10897-017-0085-8. Epub 2017 Mar 30.

PMID:
28361381
12.

Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.

Gelderblom H, Wüstenberg T, McLean T, Mütze L, Fischer W, Saft C, Hoffmann R, Süssmuth S, Schlattmann P, van Duijn E, Landwehrmeyer B, Priller J.

PLoS One. 2017 Mar 21;12(3):e0173872. doi: 10.1371/journal.pone.0173872. eCollection 2017.

13.

Progressive spinal cord atrophy in manifest and premanifest Huntington's disease.

Wilhelms W, Bellenberg B, Köster O, Weiler F, Hoffmann R, Gold R, Saft C, Lukas C.

J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):614-616. doi: 10.1136/jnnp-2016-315000. Epub 2017 Feb 16. No abstract available.

PMID:
28209652
14.

Two different phenomena in basic motor speech performance in premanifest Huntington disease.

Vogel AP, Churchyard A, Stout J, Saft C.

Neurology. 2016 Nov 22;87(21):2283. No abstract available.

PMID:
27872224
15.

Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.

Reick C, Ellrichmann G, Tsai T, Lee DH, Wiese S, Gold R, Saft C, Linker RA.

Exp Neurol. 2016 Nov;285(Pt A):12-23. doi: 10.1016/j.expneurol.2016.08.012. Epub 2016 Aug 29.

PMID:
27587303
16.

Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.

Jacobs M, Hart EP, van Zwet EW, Bentivoglio AR, Burgunder JM, Craufurd D, Reilmann R, Saft C, Roos RA; REGISTRY investigators of the European Huntington’s Disease Network.

J Neurol. 2016 Oct;263(10):2080-5. doi: 10.1007/s00415-016-8233-x. Epub 2016 Jul 19.

17.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
18.

Two different phenomena in basic motor speech performance in premanifest Huntington disease.

Skodda S, Grönheit W, Lukas C, Bellenberg B, von Hein SM, Hoffmann R, Saft C.

Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002550. [Epub ahead of print]

PMID:
26962067
19.

Treating the whole body in Huntington's disease.

Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ.

Lancet Neurol. 2015 Nov;14(11):1135-42. doi: 10.1016/S1474-4422(15)00177-5. Review.

PMID:
26466780
20.

A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington's Disease.

Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett SB, Rosser A, Saft C, Südmeyer M, Ohmann C, Schnitzler A, Vesper J; Surgical Approaches Working Group of the European Huntington's Disease Network (EHDN).

Front Neurol. 2015 Aug 18;6:177. doi: 10.3389/fneur.2015.00177. eCollection 2015.

Supplemental Content

Loading ...
Support Center